A new clinical trial investigating the safety and efficacy of Gazyva® (obinutuzumab) for adults with proliferative lupus nephritis (LN) announced encouraging initial results. The study showed that Gazyva, when used in combination with standard LN therapies, helped...
MetVital, Inc., a biopharmaceutical company developing small molecule modulators of glutamate metabolism for the treatment of diseases with significant unmet medical need and commercial potential, today announces that the U.S. Food and Drug Administration (FDA) has...
First-of-its-kind data shows efficacy and safety of a biologic in the management of axial manifestations of psoriatic arthritis (PsA), which affect up to an estimated 35 million people worldwide[1] 66.3% of patients treated with secukinumab 150 mg achieved rapid and...
New study demonstrates synergistic effects of vitamin D and estradiol deficiency on metabolic syndrome Vitamin D and estrogen have already shown well-documented results in improving bone health in women. A new study from China suggests that this same combination could...
While clinical trials tend to focus on helping patients find new ways to conquer their disease and advance scientific understanding, the patient’s experience isn’t always at the center of the conversation. The patient’s safety and well-being are always central, but...
Mechelen, Belgium and Paris, France, 11 JUNE 2019, 07.00 CET – Servier and Galapagos NV (Euronext & NASDAQ:GLPG) completed recruitment for their ROCCELLA Phase 2 trial with GLPG1972/S201086, ahead of schedule. ROCCELLA is a multi-regional, randomized,...
Email
Text